Others

Grünenthal to Acquire Bayer's Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity
BayerETR: BAYN

Grünenthal to Acquire Bayer’s Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity

Grünenthal GmbH announced an agreement with Bayer AG (ETR: BAYN) to acquire Stivarga (regorafenib) for up to €375 million, bringing the approved oral multikinase inhibitor – marketed in more than…

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World's First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World’s First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion

XtalPi's LCC Technologies Signs Drug Discovery Collaboration with Stanford University – Chiral Chemistry Meets Disease Biology

XtalPi’s LCC Technologies Signs Drug Discovery Collaboration with Stanford University – Chiral Chemistry Meets Disease Biology

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Roche's Q1 2025 Results: Pharma Sales Drive 8% Growth Amidst Flat Diagnostics
OTCMKTS: RHHBYSWX: ROP

Roche’s Q1 2025 Results: Pharma Sales Drive 8% Growth Amidst Flat Diagnostics

Show More